
Evaluation Only. Created with Aspose.Words. Copyright 2003-2023 Aspose Pty Ltd.
          !
• #   $ # %&'(# 
& ) $*+# , - ./   0. 1 #2 12 +0#1  3!4 1
#   0#1 )    0#1 ) 
!  0#1  )5 ! )   
+6  0.   2549 
# & ' 5 ! )   
PREVALENCE AND SEVERITY OF ALLERGIC DISEASES IN THAI CHILDREN IN PHITSANULOKE 
Ms. Wilee Sumritwatchasai 
A Thesis Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science Program in Pediatrics Department of Pediatrics 
Faculty of Medicine 
Chulalongkorn University 
Academic Year 2006 




     
#%&$  ' " &(&('  ) CF&? 'E ?&&F?  % G?  ' '  " CF?  &?A&f'K        
" CF?  ) CF  ?&{  )?'   &?c G&  @ ) !' 
fAB (! &   "'?   F&G%   ?!O O
c  KCF&?'E ? )  k F   F' ' 'K       " CF? ) CF? & { )?'   
c  KCF& ? | ? &  &?A&f'  K      CF?  ) CF? &{  )?'  
•   &? ?'E #  '?  &?A&f'  K    
   K"   LG   "#$'K F'    @ ) !'  #"'$
! & OO 
G )c A  " #$ "K  @" K! CB (O O
   c #&   G )G    @"APf !& G 
K"'J ## F#  

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/

  
   
•  . .. ...........................................................................................................
•   .........................................................................................................  ............................................................................................................... ............................................................................................................................... ....................................................................................................................! " #....................................................................................................................$
• %&1   (......................................................................................................................1 ) (*+& %,  )................................................................................1 (-,  ).....................................................................................................2 )-/ , 0 ).............................................................................................2 ( ( )& 1  %1 )......................................................................................3 3 0& % )   ... ........................................................................................7 
• %&2   ))5 ...............................................................................................8 
• %&3 )7%8(  )....................................................................................................10  8)+ (:...............................................................................................10 +( ,;  1 8  <+ ). .........................................................................11 
• %&4 <+ ).............................................................................................................13 
• %&5  )50..............................................................................................................41 
•  /*+, 8  *...........................................................................................44 
   ...................................................................................................................45 <).........................................................................................................................48 )<"8,% )#70...................................................................................................59 

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/
   
  
 1            ..............13 
 2   #$ #$   % & '#  ) *+ , ((... .....14 
  
 3   #$ #$   *   Allergic rhinitis............17 
•    
 4   #$ #$     :Allergic rhinitis ......................18  
•    
 5   #$ #$ :    #  All ergic rhinitis  ...................19          
>>% > ?  @ :      
6   #$ #$   *    Asthma ......................20 
•    
 7    #$   %  $  Intermittent  # $  FFF ..............23 
Persistent      
 8   #$ #$  ( H  Atopic dermatitis     .2 F5 F  9   #$ #$( $L (  Atopic  dermatitis  FFFFFF .26 
•    
10  #$ #$*  '@ # $ *LFFF. FFFFFF 27  
Atopic  dermatitis     
11    #$ #$ :  Atopic  dermatitis  ) FFFFFFF 29   
   
 12   # $#$( $L (  Urticaria    .. .........30  13   # $#$ :  Urticaria  )     .FF F..31  14   # $#$%$ +   L (     32  F  15   # $#$    Food  allergy    .. ........33  16  *  P ? % & '#  ) *+ , (( (   QFFF ....35  
L R   6-11.9 %T 
17  *  P ? % & '#  ) *+ , (( (   Q.............37 
L R   12-18 %T 

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/
   
  
 18%*   P? %& '#  ) *+ , (( (  Q....F .FF 38 
L R
 19   #$ )* +,(   (Comorbid  disease) FFFF ...FF ..39   
L R   6-11.9  %T 
 20   #$ )* +,(   (Comorbid  disease) ...........................40 
L R   12-18  %T 

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/

    
  
1       !"#    $% $ &&&..& &&& 15      2        Allergic rhinitis   $% $ .. ........................16 3       %7 89 "  Allergic rhinitis   $% $ .1 6 4  89     ;7  <# = "> Allergic  rhinitis ...................18  
• $% $   
5    exercise induced bronchospasm&&&&&&&&&&&& & .20   
•  asthmatic attack in past 12 month  $% $   
6     ! ">  Asthma  !# J "#    $% $ &&&.2 &1 7    . #J "#  !  ">  Asthma   $% $ .2 1  8     exercise induced bronchospasm ! Intermittent   &&& ....22 
Persistent  asthma   $% $   
9     asthmatic attack in past 12 month ! Intermittent   &&& ...22 
Persistent asthma   $% $   
10         Allergic conjunctivitis   $% $ ..& && 24 11     ">  Allergic  conjunctivitis   $% $ .. ....................24 12    ">  Atopic  dermatitis  #7 # $  Systemic&& .28    
•  Local treatment   $% $   
13    ">  Urticaria  #7 #   $Systemic     Local ..31           
Treatment  $ % $  

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/

1
  
•    
     !!" ! #$ %&%  '(% )" 
  * +   %+ '% ,)&   , # -  &% &, , #+  - +( 
  , # -%! &,   '%%  , #. & -  
)% #(%$ /       ) +(  0% &    1 #$ , +%  )
% !!. 2   %     (%  ) "&"!, +!/&  !3 !& 0
 %   )/ ( !.%  "3  & ++'&  *&%,
 %+&  +%  + (,% (.3%  &$ "4,+, +&,
%,+ &%.3, "  . *  +  Th2   &, + (Hygiene 
Hypothesis) ( 1 )
#$ , +%  *!+ % !!% !%&  ,%   + , +%  !!,  E(% )"(Prevalence)   &,  #$ E  !! (Risk factor) !,  E
 3("&,+.    O !,.*%  %  E $3 E( 
(% )"  (Prevalence ) 3 E !.% ,)   &%)") 0(
! . % ,)  1 3 +  
- Point prevalence O!.% ,) 0% ) %& %!   .)  )% %& 1  P 
- Cumulative prevalence O !.% ,)   0  (&% +)( ,)0 
   *+  & +, '/3 2 +!     +%3 &  *+ 3O+ 
(asthma)  ,  O "!    ! (a llergic rhinitis) ,  O "( !  (allergic 
conjunctivitis) , /O%3/ (atopic dermatitis) , &  , $     &,  3

Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/
9
•    
1.  +'*!3% + &$4 "% )"   ( 0  !!"    * 2.% "   (  0  +'*! 3% + $ 4& "  (( !! 3%+ O03O  *
 *  
3. $   (  0     *
   
1. O# $3% ) "   ( &,)+ +'  , E )#$ &,) Y $ #   ! 3%+ $4"  &
2. #$% "     ( 0  +' ) ,E #$  &,)Y #$  
! 3% + $4"  &
3. 3%  , Y3 Z%   &, !!( 0
•    !"# !   
$ %&  (Asthma) 
•    &,  +  & (  .! . +%  3O+( Z  & P
.#.2536 (Global Initiative For Asthma .#. 1993)  ( 2 ) O
1. " + 3& +&   O  &," +  E.3 &+  & *+ +  )
3& +& 3O !!,3 *  +(chronic reversible airway obstruction) 
2.     3&+ & (airway inflammation) 
3.   % *% 3& +& ( , ((" 0 (increase airway responsiveness to variety of 
stimuli) 
GINA(Global Initiative for asthma) 2004 ( 3 ) % "   3O+(  +  (  
Classify Asthma Severity 

$ 8&  98  :9 ( ;A#llergic rhinitis) ( 4, 5, 6  )
3O ,))   %g   #h    + ! O,  "    . 
/+   (&,     *+   O "!   ! O  ! !  +!  
 . *3  &% "  ((  *  ( &, ( ( !E  " 
 !!" WHO-ARIA  ( 7 )*+ % "     !    !  (  ,, %&    2   O
1. !   !  03 ( 0Intermittent allergic rhinitis) 3 E  
/ m%      %4 % ( +3Z 3O  % 4   +3Z( P 
2. !   !  (   O(Persistent allergic rhinitis) 3 E     
% 4  % (+3  Z3O % 4  +3Z(  P
&, mild  3 E *  + (*  
- 23 3&
-  !. +  .!%(  ,% !. &,3O  .&   
- 23  % 3 3O  O.  
Moderate to severe 3 E   +* (    1  O 
- 23 3&
-  !. +.!%(% ,! .&,3O   . & 
- 23 %  3  O 3.  O 
$ 8&  8  :9 ;#(Allergic conjunctivitis) ( 8, 9, 10  )
•    +   conjunctiva +&* Type-I hypersensitivity /  IgE +
q&  *+ &, 10-20  ,)%* %32&%!,  %     !  % % 
allergic rhinoconjunctivitis  / m%%32 !,,% (  %   !     r+   &, r+0  ) 32!,   % ) 4 &,  32
 #      P) m*, s"'+! &  (%Z &   (
•  &,  +    O"(   ! ! ,   ( .(*3&   (  O( 
( % +   !, +  (   0  &,  +%  ! .*3&  +!  
• 0!,  ( * (ph *+otophobia) 
$ B&:9 B ;# % (Atopic dermatitis) ( 11, 12, 13  )
&$4,.  2O     /% 3   O    / %3  3 /O  +% 
 3. &O ,,  ,, O /%3 !,3 (lichenification) &, 3  ! + (+ )O
/ %3 *+ + q ,! ) OStaphylococcus aureus %32 / m% !, ,%(   % 
+ q ,/m%  &,    % &"!,,+ IgE   +  '%&,  
+ O   / O!, $4 &, ((   * ( ,,  &,( %  +'  + *+ 3 % +   
1. %   ( Infantile atopic dermatitis) /O  +% 4 3    (  /O  !,
  %  4extensor surfaces     %4  3 3 #$,!, 3 &,  "
• +3O3 * *+   3  P
2. % +' (Childhood atopic dermatitis) /O1* 3* !%  ! ,  &   /OO  
.3&$4, /3O (atopic dermatitis)  &, 3  " () +!
 %4      O    &,  %4 &O(  3  O ! , 3  
/O + 3(% (hyp erlinear palms) 
3. % "&,% 3 / 2 (Adolescent or adult type  atopic dermatitis) (. 3  /O& 
childhood type  (  O hand eczema , nipple eczema  &, %43 /  
3% %
!, 3' *+ %  +. !   O &, E+.    %3 /2*+ ! 
  ) +3  3+ 23 + ) ! +& $  &, 3 + 23 ( 
%  +'&,. % /3 2 
$  ;E (Urticaria) ( 14  )
&  3 $OUrticaria 3 E  % . )dermis  30 (wheal) %    reflex 
hyperemia  0 (flare)  &, % +%  & $ 4,! ,.  Type-I hypersensitivity 1 +! 3&vasoactive amines ! skin mast cell +%* !,* ce ll infiltration 3OE   ' + /O ! "
'%3&!.E++1&  ,  &O+ 1/O! 3* *+   30  E6 ) % +!,* ("
3O     3& 3&O3 3' ! E& !  & $  * +   , 4
 &, 15-30   ,)% *% +' *+ , 4 3-6 % %32 !, & $ & q
;# (Drug allergy) ( 15  )
y  *  , Z!  (Adverse drug reaction, ADR)  ! *+ 
Type A   y %pharmacologic action  ( % 0+%32 /m% %*  O* + + (3 .  $  p redictable reaction  &, dose-dependent   )overdose, secondary or indirect effect, side effect  &, drug interaction  *+ , 4 80%  ADR  3+ 
This document was truncated here because it was created in the Evaluation Mode.
Created with an evaluation copy of Aspose.Words. To discover the full versions of our APIs please visit: https://products.aspose.com/words/
